
We are turning this account into a fully automated page. To learn more about what’s going on at Immunity, please follow us on LinkedIn! linkedin.com/company/immunit…

Cutting-edge research in immunology from around the world. This account is no longer monitored, and content is automated. Join us on LinkedIn!

We are turning this account into a fully automated page. To learn more about what’s going on at Immunity, please follow us on LinkedIn! linkedin.com/company/immunit…

Online now: The transcription factor TOX maintains stemness circuits that sustain longevity and multipotency of progenitor CD4+ T cells in chronic infection dlvr.it/TWMs1C

Online now: Brain border-associated macrophages rhythmically scavenge amyloid-beta and regulate vascular amyloid pathology dlvr.it/TWMkrb

Online now: Human interferon-α autoantibody development broadens reactivity and enables functional synergy dlvr.it/TWKGnP

Be part of three days of science, discussion, and connection with Tak Mak @UofT and the international neuroimmunology community at #CPSNeuroImmune27 @NYAMNYC. Abstract deadline: April 30, 2027 hubs.li/Q04F6KQK0

Online now: Granzyme K is a driver of age-related tissue remodeling and functional decline independently of age-associated immune dysfunction dlvr.it/TWJW3v

Looking for a home for your neuroscience research? Chat to Kavitha Scranton, scientific editor at @ImmunityCP. She’ll be happy to discuss publishing opportunities and tell you why Immunity could be a good fit for your work. Book an online meeting: hubs.li/Q04DzxCk0 #SfN26

🔔 Check out this #OpenAccess @ImmunityCP review providing an overview of the current applications, the challenges and limitations, and future avenues of human brain cellular #xenografts in neuroimmunology and translational research! 🔗 bit.ly/4zvDjIJ

Share the stage with researchers including Chengcheng Jin @PennMedicine at #CPSNeuroImmune27 in New York. Submit your abstract by April 30, 2027, for the opportunity to be part of the program. hubs.ly/Q04DKHtx0

Discover the latest research from Vinny Augustine @UCSanDiego and an outstanding international community at #CPSNeuroImmune27 in New York. Abstract deadline: April 30, 2027 hubs.li/Q04DyPVC0

1) 📢 New study out in @ImmunityCP : We show that tumor-to-cDC1 reprogramming induces tertiary lymphoid structures (TLSs) across cancers. Read it here:sciencedirect.com/science/ar…. A thread 🧵 #TLS #reprogramming #immunotherapy Graphical abstract by Avesta Rastan.

Online now: Tumor-to-dendritic cell reprogramming induces immunogenic lymphoid structures across cancers dlvr.it/TWBfLG

Online now: Mitochondrial DNA abundance is a determinant of immunogenic cell death in cancer dlvr.it/TW6zH0

Online now: Growth factor VEGF-B sustains intestinal Tfh cell stemness to restrict Taurinivorans outgrowth and microbiota-driven obesity dlvr.it/TW6F82

Efficacy of PD-L1×4-1BB antibodies relies on PD-L1+ cDC1, which integrate antigen cross-presentation, IL-12, & 4-1BB costimulation to promote efficacious T cell-mediated antitumor immunity cell.com/immunity/abstract/S… @ImmunityCP @DrIgMelero @ClinicaNavarra @Teijeira_ITLive 🇪🇸

PD-L1 on B cell zone reticular cells, including follicular dendritic cells, promotes humoral immunity by restraining a subset of Tfh that promotes Tfr development @ImmunityCP @eakamagarren @BostonChildrens cell.com/immunity/abstract/S…